Abstract
The search for novel, effective, and safe psychotropic medications for use in children and adolescents is an ongoing journey. Specifically, several atypical antipsychotics have received FDA indications for use in children and adolescents, although carry the risk of potentially serious side effects such as extrapyramidal symptoms, tardive dyskinesia, weight gain, metabolic syndrome, and symptoms of hyperprolactinemia. Three newer antipsychotics – asenapine, iloperidone, and lurasidone – have been considered by some as alternatives to use in children and adolescents with various psychiatric conditions. However, the data on the use of these medications in this population is limited. We review the current literature regarding the use of these agents in children and adolescents. Although these medications may have similar properties to current agents with approved indications, there is not sufficient evidence at this time to recommend their use in children and adolescents. More research is needed regarding the efficacy, safety, and tolerability of these medications in the pediatric population.
Keywords: Adolescents, antipsychotics, asenapine, children, iloperidone, lurasidone.
Current Psychopharmacology
Title:Safety Profile of the Use of Second Generation Antipsychotics in the Child and Adolescent Population
Volume: 3
Author(s): Michael Shapiro, Mariam Rahmani, Adrienne Eisner and Mathew Nguyen
Affiliation:
Keywords: Adolescents, antipsychotics, asenapine, children, iloperidone, lurasidone.
Abstract: The search for novel, effective, and safe psychotropic medications for use in children and adolescents is an ongoing journey. Specifically, several atypical antipsychotics have received FDA indications for use in children and adolescents, although carry the risk of potentially serious side effects such as extrapyramidal symptoms, tardive dyskinesia, weight gain, metabolic syndrome, and symptoms of hyperprolactinemia. Three newer antipsychotics – asenapine, iloperidone, and lurasidone – have been considered by some as alternatives to use in children and adolescents with various psychiatric conditions. However, the data on the use of these medications in this population is limited. We review the current literature regarding the use of these agents in children and adolescents. Although these medications may have similar properties to current agents with approved indications, there is not sufficient evidence at this time to recommend their use in children and adolescents. More research is needed regarding the efficacy, safety, and tolerability of these medications in the pediatric population.
Export Options
About this article
Cite this article as:
Shapiro Michael, Rahmani Mariam, Eisner Adrienne and Nguyen Mathew, Safety Profile of the Use of Second Generation Antipsychotics in the Child and Adolescent Population, Current Psychopharmacology 2014; 3 (2) . https://dx.doi.org/10.2174/221155600302150302112302
DOI https://dx.doi.org/10.2174/221155600302150302112302 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Off-Pump Coronary Artery Bypass Grafting; is it Still Relevant?
Current Cardiology Reviews Gene Polymorphism of Angiotensin II Type 1 and Type 2 Receptors
Current Pharmaceutical Design Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry Necrotizing Enterocolitis: Clinical Features, Histopathological Characteristics, and Genetic Associations
Current Pediatric Reviews Amelioration of Myocardial Ischemic Reperfusion Injury with Calendula Officinalis
Current Pharmaceutical Biotechnology Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders
Vascular Disease Prevention (Discontinued) Inducible Nitric Oxide Synthase - Time for Reappraisal
Current Drug Targets - Inflammation & Allergy Toll-Like Receptors and their Role in Renal Pathologies
Inflammation & Allergy - Drug Targets (Discontinued) Redefining the Role of Long-Acting Phosphodiesterase Inhibitor Tadalafil in the Treatment of Diabetic Erectile Dysfunction
Current Diabetes Reviews Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Neuropeptide Mimetics and Antagonists in the Treatment of Inflammatory Disease: Focus on VIP and PACAP
Current Topics in Medicinal Chemistry From the Oxygen to the Organ Protection: Erythropoietin as Protagonist in Internal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Non-Analgesic Effects of Opioids: Opioid-induced Nausea and Vomiting: Mechanisms and Strategies for their Limitation
Current Pharmaceutical Design Medicinal Plants and Bioactive Compounds for Diabetes Management: Important Advances in Drug Discovery
Current Pharmaceutical Design Levosimendan: A New Inodilatory Drug for the Treatment of Decompensated Heart Failure
Current Pharmaceutical Design The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results
Current Cardiology Reviews Catheter-directed Thrombolysis <i>versus</i> Systemic Anticoagulation for Submassive Pulmonary Embolism: A Meta-Analysis
Current Cardiology Reviews